

Catalog# BP- 50573

Clenoliximab Biosimilar (CD4 Monoclonal)

Clenoliximab Biosimilar uses the same protein sequences as the therapeutic antibody clenoliximab.

Clenoliximab is a chimeric monoclonal antibody from Macacairus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) that binds specifically to the CD4 receptor present on T-lymphocytes (Helper T lymphocytes). CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA). Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lymphocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lymphocytes in circulation.

Product Details	
CAS No.	182912-58-9
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Clone	Clenoliximab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD4
Purity	>95%
Molecular Weight	~150kD
Protein Concentration	1 mg/ml
Formulation	0.2 μ M filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.